Clinical Trials
15 trialsNCT07383441 2026-06-11
Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer
SWOG Cancer Research Network
Phase 3 Recruiting
NCT04955743 2026-06-04
Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma
Yale University
Phase 2 Terminated
NCT07405164 2026-05-29
MK-6482-043
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT04626479 2026-05-18
MK-3475-03A
Merck Sharp & Dohme LLC
Phase 1/2 Active not recruiting
NCT04977453 2026-05-15
Keynote B59
GI Innovation, Inc.
Phase 1/2 Recruiting
NCT07571551 2026-05-11
TRIPLE-PATH
Jinling Hospital, China
Phase 2 Recruiting
NCT07384416 2026-05-08
QL1706 Plus Lenvatinib in Previously Treated Penile Cancer
Sun Yat-sen University
Phase 2 Recruiting
NCT04626518 2026-05-06
KEYMAKER-U03
Merck Sharp & Dohme LLC
Phase 1/2 Active not recruiting
NCT04736706 2026-05-06
MK-6482-012
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT04586231 2026-05-05
MK-6482-011
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT05327686 2026-05-04
SAMURAI
NRG Oncology
Phase 2 Recruiting
NCT06138496 2026-04-21
Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC
Sun Yat-sen University
Phase 2 Completed
NCT04393350 2026-04-20
Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma
Emory University
Phase 2 Active not recruiting
NCT05024214 2026-03-25
Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
3D Medicines
Phase 1/2 Recruiting
NCT05733715 2026-03-24
Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma
Abramson Cancer Center at Penn Medicine
Phase EARLY_PHASE1 Recruiting